![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Antoniu Sabina Antonela
Publisher: Informa Healthcare
ISSN: 1472-8222
Source: Expert Opinion on Therapeutic Targets, Vol.16, Iss.4, 2012-04, pp. : 355-363
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Targeting PDGF pathway in pulmonary arterial hypertension
Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 11, 2012-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tadalafil: In Pulmonary Arterial Hypertension
By Croxtall Jamie D. Lyseng-Williamson Katherine A.
Drugs, Vol. 70, Iss. 4, 2010-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Terguride for pulmonary arterial hypertension
Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 11, 2011-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sitaxentan: In Pulmonary Arterial Hypertension
Drugs, Vol. 67, Iss. 5, 2007-01 ,pp. :